Featured Research

from universities, journals, and other organizations

Potential new strategy to treat ovarian cancer discovered

Date:
April 28, 2014
Source:
Manchester University
Summary:
A potential new strategy to treat ovarian cancer has been identified by researchers. Recently developed drugs have increased patient survival rates by targeting a tumor's blood vessels that supply essential nutrients and oxygen to cancer cells. However, many patients go on to develop resistance to these therapies and grow new blood vessels that spread the cancer again. Ovarian cancer is the deadliest of all gynaecological cancers, and since the majority of patients are diagnosed when the disease is at an advanced stage, prognosis is generally poor.

Scientists studying cancerous tumor tissues in a laboratory believe they have identified a potential new strategy to treat ovarian cancer -- which affects around 7,000 women in the UK each year.

Recently developed drugs have increased patient survival rates by targeting a tumor's blood vessels that supply essential nutrients and oxygen to cancer cells. However, many patients go on to develop resistance to these therapies and grow new blood vessels that spread the cancer again.

A team from The University of Manchester -- part of the Manchester Cancer Research Centre -- say blocking several avenues that tumor cells use to escape eradication at the same time is now the way forward rather than current drugs, which target only one molecule.

The research gives scientists the opportunity to develop new anticancer drugs that target ovarian tumor growth through the inhibition of the development of new tumor blood vessels.Ovarian cancer is the deadliest of all gynaecological cancers, and since the majority of patients are diagnosed when the disease is at an advanced stage, prognosis is generally poor.

Currently 7,000 women are diagnosed with the disease in the UK each year. Of those, more than 4,000 are not expected to survive but if women are diagnosed earlier 90% of those cases could beat the disease.Scientists looked at the role of a particular set of molecules in controlling the activity of growth factors, proteins that are responsible for the stimulation of blood vessel growth.

Dr Egle Avizienyte, who co-led the research with Professor Gordon Jayson, said: "We know that a molecule called heparan sulphate (HS) is involved in blood vessel growth through facilitating interactions between the growth factors and their receptors that induce the development of new blood vessels. This is controlled by proteins known as HS6STs which regulate HS structure.

By knocking down these proteins -- reducing their levels in cancer cells -- we were able to reduce activity of growth factors and stop ovarian cancer cells inducing the development of new blood vessels.

"The studies in tumor tissue in the laboratory showed that reducing HS6STs led to a reduction of tumor growth.

Professor Gordon Jayson, who leads the research group, said: "This knowledge gives us the opportunity to develop new anticancer drugs aimed against these growth factors. Targeting multiple factors and blocking several avenues that tumor cells use to escape eradication at the same time may be a better strategy than current drugs, which target only one molecule."


Story Source:

The above story is based on materials provided by Manchester University. Note: Materials may be edited for content and length.


Journal Reference:

  1. C. L. Cole, G. Rushton, G. C. Jayson, E. Avizienyte. Ovarian Cancer Cell Heparan Sulfate 6-O-Sulfotransferases Regulate an Angiogenic Program Induced by Heparin-binding Epidermal Growth Factor (EGF)-like Growth Factor/EGF Receptor Signaling. Journal of Biological Chemistry, 2014; 289 (15): 10488 DOI: 10.1074/jbc.M113.534263

Cite This Page:

Manchester University. "Potential new strategy to treat ovarian cancer discovered." ScienceDaily. ScienceDaily, 28 April 2014. <www.sciencedaily.com/releases/2014/04/140428120801.htm>.
Manchester University. (2014, April 28). Potential new strategy to treat ovarian cancer discovered. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/04/140428120801.htm
Manchester University. "Potential new strategy to treat ovarian cancer discovered." ScienceDaily. www.sciencedaily.com/releases/2014/04/140428120801.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins